Insmed Reportable Segment — Provision for income taxes decreased by 5.5% to $1.47M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 60.6%, from $912.00K to $1.47M. Over 3 years (FY 2022 to FY 2025), Reportable Segment — Provision for income taxes shows an upward trend with a 53.7% CAGR. This is a positive signal — lower values indicate better performance for this metric.
An increase typically reflects higher taxable income within the segment, while a decrease may indicate lower profitability or the utilization of tax credits.
This represents the total tax expense recognized by the specific business segment for the reporting period. It reflects...
Standard across biopharma segments, though often minimal for early-stage or loss-making segments.
insm_segment_reportable_segment_provision_for_income_taxes| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $345.75K | $345.75K | $345.75K | $345.75K | $638.75K | $638.75K | $638.75K | $638.75K | $589.00K | $838.00K | $1.01M | $1.27M | $912.00K | $1.24M | $1.32M | $1.55M | $1.47M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +84.7% | +0.0% | +0.0% | +0.0% | -7.8% | +42.3% | +21.0% | +24.9% | -28.0% | +36.3% | +6.2% | +17.5% | -5.5% |
| YoY Change | — | — | — | — | +84.7% | +84.7% | +84.7% | +84.7% | -7.8% | +31.2% | +58.7% | +98.2% | +54.8% | +48.3% | +30.2% | +22.5% | +60.6% |